Drug intelligence / Profile preview

BCWP-D019

Development stage: Preclinical
Lead developer: BC World Pharm
Modality: Small Molecules
Administration: Subcutaneous, Intramuscular

Overview

BCWP-D019 is a long-acting injectable small molecule formulation being developed by BCWorld Pharma for the treatment of obesity. Currently in the preclinical formulation research stage, the drug is designed to be administered once monthly. The program utilizes BCWorld Pharma's proprietary drug delivery technology to create a sustained-release profile, aiming to improve patient adherence and weight management outcomes compared to immediate-release alternatives. The specific active pharmaceutical ingredient and biological target have not been publicly disclosed.

Other names: BCWP-D019BCWP-D-019BCWP-D 019

Beyond the preview

Go deeper on BCWP-D019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCWP-D019.

Explore the full profile